Earnings call transcript Q2 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode.

Following the presentation there will be a question-and-answer session. Please be advised that today's conference call may be recorded.

I would now like to hand the conference call over to Alexis Callahan, Head of Investor Relations at Esperion. Alexis. ahead, go Please

Alexis Callahan

members Good Conference welcome are Call. CEO following CFO. President Operator. be team Quarter for available Sheldon Esperion's XXXX and Q&A Other Halladay, Ben Earnings With prepared and the morning you, executive to will remarks. and our Second Koenig, of Thank us today

caution covered will Securities callers Harbor with provisions Safe forward-looking the making business. remind to discussed and Litigation want risks Actual differ the Act. the information results uncertainties management by due on statements materially stated the under Private listeners the forward-looking statements. I from associated to that our call be or Reform I today that is could of implied those

contained The August press to statements We SEC events this of live accurate in in XXXX. our These the that of time-sensitive content date and and undertake today's the entirety forward-looking statements conference forward-looking are statements any in X, release filings. update qualified conference as is of their call obligation broadcast, information webcast. call this no to circumstances only or after contains cautionary by this of or date reflect the revise

our this a the call. recorded are and call archived. We website. can be morning and copy A Investor issued reminder, webcast of content the a press As page this conference earlier today's release being detailing of on found

for your the with then call the prepared questions. begin will line and We remarks open

the turn call Sheldon President now I'll Officer. to Chief Koenig, and over Executive

Sheldon Koenig

progress second joining today and you to morning, for made. discuss good our recent results the Alexis quarter us everyone. you Thank and Thank we've

each quarter. to continuing is grow business Our

awareness brands for XX% U.S. of solid attribute as our the the our million business commercial is million, year-over-year. as data, as our our XX% are prepare full of and launch. execution clinical well to We increased strategy We reported of reflecting to a for in U.S. strength second we of quarter $XX.X total year-over-year which We pleased report increase $XX.X revenue, growth. revenue

new in and and prescription since by highs quarter. first ACC weekly released second our grew quarter retail in the bolstered regularly XX% NEXLETOL the equivalents year-over-year, from prescriptions quarter, Second data additional in NEXLIZET hitting we've been presentation

robustness New-to-brand grow cardiovascular at growth the ACC prescriptions through impressive second presented data period by Outcomes, by In reduction risk new-to-brand in of the have showed also primary at our XX% prevention presented ACC March driven June. of we June, prescriptions. first ADA to and continued from the end the in in data

NBRx XX% For increased the second by quarter-over-quarter. quarter

next from me additional Let walk the highlights through you quarter. key some

saw XX% As continued I RPE mentioned, quarter the we in growth of second just year-over-year.

We are footprint. current pleased and trend with promotional a we've to which able label with this been accomplish

we As the EU second and our in submitted promised, both meaningfully labels filings jurisdictions. U.S. in our both expand to during quarter regulatory the

compile required tirelessly Outcomes of this trial regulatory proud teams Our amount these execution. out and which comes of for to of their worked scale we're data clinical and submissions vast the over the and

expanded the both anticipate standard EU in in XXXX. half first U.S. for We XX-month the and submissions labels expect review therefore regulatory of approvals both of and a

the for believe following way change. significant label the will pave to growth continuing are We we result

strategically the educate effectively segments presenting the the different a commercial market enables target relevant targeted involves to regular us cadence, Our audiences approach of which to right and at analysis population.

clinically In This LDL Congress, meaningful Association prevention in only Association that the clinical risk we the are was and of who our already reinforcing meaningfully who American of patients showed prestigious are simultaneously significance. at not our its cholesterol. market. high in cardiovascular event, American primary one which June, but addressable impressive Medical expand also and analysis in This primary a Diabetes risk presented affected the had have at means cardiovascular data prevention new published Journal therapies reductions and significant

treat to statins which inhibitors. on intention demonstrating is better and and the comparable to improved of than We consistency analysis also benefit, Society at treatment Outcomes new Congress PCSKX and Endocrine presented

results will Cardiology at the European We two the at fit, present in congresses late-breaker and to we right of meetings the continue year including August. Society level throughout presentations the believe are highest

share We force QX, as are who over ramp our We up partnership look in pleased in quarters. forward with in to increased Esperion territories seeing joined time to that XX another their additions new launched these in-house did Currax territories. subsequent as sales traction early members new

to Feedback positive and positive lives. we've and benefit the have our the larger pharmacy presented and total potential payers managers extremely now U.S. is across XX% Lastly, by much have we status reflect on to with are data, we current board of Based data. conversations CLEAR group we to payers represent has Outcomes over already date, adapting been continue to pharmacy label. to national payers a that CVOT characterized patients believe of utilization our benefit our management Outcomes criteria who

diagnosed Our small ASCVD subset who their familial cannot hypercholesterolemia on atherosclerotic label cardiovascular indicated a and tolerated disease, goal a with maximally current is heterozygous of patients meet statin. for

both limitations indication and of populations, expanded the new primary risk including broad a add Our as requirement label a tolerated maximally well secondary in therapy. and as cardiovascular statin will reduction remove current

From a perspective, patient expansion able label be meaningfully to increase we'll our commercialization means population. adjustable

million cholesterol documented are total patients maximally U.S. tolerated LDL a who population approximately covers with the the their increases and Currently, not data ASCVD goal. Outcomes still to label on in are alone. XX at addressable patients CLEAR our statin million XX Our approximately who

million be ASCVD additional statin XX untreated these represents will with potential not upside will risk an our prevention patients for post the high that Our additional focus taking total, intolerant. are high only new also from us and at XX treat In on enable but population, change patient the patients with plus who patients million or which million label risk patients. who are risk ASCVD label population, primary XX high million to statin, X another

goals to reach alone. therapies able who more We being unable are confident blockbuster look NEXLETOL on commercial cholesterol patients have current to that even and are we forward LDL their NEXLIZET and to potential achieve

I quarter over it will Ben that, more of Financial Chief to Officer now a our for performance. Halladay, hand our detailed overview With second

Benjamin Halladay

containing morning, the on Earlier issued note my a results we Investor this quarter, otherwise Sheldon. the Thank second second our is that comments for Please reflect results the website. ended quarter press for unless release our you, page XX, specified, available of which financial June XXXX.

also quarter of The we growth our quarter-over-quarter. strong XX,XXX We in surpassed Overall, demonstrated RPE quarter, prescription we're CVOT impressive recently reflecting the RPE posted positive during and data. trend the persistent and second year-over-year results. continuing which mark proud XX% equivalents to reception XX% increased have weekly is retail

its these treated important medicines the of patients the May, sequential clinicians continues value in bring patients territories, showcasing our Europe, partner therapies to they European the care Our our to in three-month have At strong report of with February. been representing of growth growth XX% XXX,XXX now end therapies and since for.

addition the products had second our quarter at a in territory the with also new end Italy. launching of We

results to our the Turning quarter. financial for

As revenue of $XXX.X representing year-over-year. XX, June on was of royalty XX% reported for investment an $X.X XXXX. million December XXXX, an combined available totaled cash, Collaboration which of We million and equivalents compared securities increase U.S. partner XX, increase sale $XXX.X million, $XX.X and includes X% year-over-year. of revenue, million, revenue cash product

XX% million, Finally, for quarter total year-over-year. was of increase $XX.X second an revenue the

XX XX% goods product collaboration to primarily last of sales by which to already this the cost lower shipments to in due next an anticipate through second year, tablet We've than which tablet expenses, expect additive the partners decreased of for of over increase quarter expectation demand. of July, for was be elevated third sales to acceleration our mirror the shipments. seen will cost goods therefore Turning months to sold the original driven our quarter. is an sold timing $X.X We and million,

full R&D for costs the study. million decrease operating readout SG&A million, with expense $XX.X total of million we as tracking million expense. reflecting well as year-over-year, $XXX XX% was contract to guidance. force in $XXX expect higher our costs. year-over-year, to sales lower are out an reflecting was increase $XXX $XXX of between following expense Outcomes year that $XXX million to still our R&D XX% in to line training and legal expense upfront of We $XXX $XX XXXX and million, breaks a expenses CLEAR costs SG&A This million in million, and be

As be the loaded of half first to half moderate expenses and operating our back in to reminder, are expected the a year.

prudent I wanted to management now and to over further and cash the elaborate year. next approach our on expenses

expanded have label payment. to to and we First, runway and milestone take mid-XXXX, of currently we which will guided having through when corresponding sufficient us new our receive approval cash expect beyond

the quality in Second, while we to year. internal will generate our spending the additional we commercial are our look of full for we the in quarter, planning changing XXXX, half we are second continue to did efficiencies expense impacting and expectations without outperform XXXX back the opportunities guidance launch for of not next

the internal investment, continued of include growth. as slower as which occur control cost levers against These backdrop well pipeline will sales

Our are of working in remainder plan massive and is sights of potential our we the scale these With for continued initiatives on and steadily for commercialization NEXLETOL franchise, execution year mid-XXXX. set to as the full approach of goal. our NEXLIZET the we reach prudently our

Sheldon. let it With over to now you, back that, me hand

Sheldon Koenig

from Thank corporate additional provide quarter. you, updates now the I'll Ben.

through patent First, five extension, of we our periods received review finality mid-XXXX. the which our term a extend of the recently would requested matter the letter FDA patent regarding regulatory another from for determined years composition by

extension of the were As several we in months. receiving certificate next this no filed, oppositions anticipate

Second, Gibson XXXX an legal amended requested. April, against the at has trial as date European complaint we hear Dunn the our filed team court partner set to our

with We $XXX being in that are that believe matter milestone will the remain will are pleased is treated our case entitled confident sense urgency that contractually we our payment we to. we of and favor a receive be this million and resolved

the our promises emphasize We prudent plan. sales and expansion following working once and diligently expense execution continued I true Lastly, on again are inflection expect to commercial for launch. to our heads strategic quarter. We management delivered label preparing second for our goal full that want on in the come down growth still toward focus of and

reiterate for to achieve blockbuster Next, I franchise. like would our plan our status to

First robust data.

data, Outcomes healthcare remarkable powerful landmark high Our patient to analysis subgroup a of quality are relevant trial us XX,XXX providers. that to enables produce generated which extremely amount

will data be our highly Next, a support differentiated label. used to

to the globe and adjunctive a Following to expect guidelines updates across treatment shift see meaningful this utilization. therapy label physician expansion, in we

initiatives growth prudently label our providers expansion in and execute year. and Finally, plan payers continuing ahead working on strategic we our of alike healthcare to next educate to investing are

made up today this reminder a I has with deliver leadership team commitments of on. would like the wrap to comments and continues to our

XXXX. First, we just fall following the company of promised to deliver did We that. our consistent reorganization growth in

of accelerating Second, we spring promised XXXX. growth to readout CVOT following in our show the

we mid-XXXX, just full commercial will and and expansion following We third, in that. to are doing do promised launch label we exponential growth that, demonstrate and

the and of entire unwavering proud Plenty remains of am to to want done, I I to commitment our we thus thank work for towards have Esperion the ability our look and in be to its made succeed progress team this to I have continued forward demonstrating progress but far. work tireless confidence goals. vision.

And Q&A. with that ready now are we for operator,

Operator

you. line from Ding Instructions] first of come [Operator Jefferies. will question Dennis Thank Our from

line Your is open.

Dennis Ding

morning. guidance, at Thank implying that more line? in R&D be date more is and questions. me, date you really you've talk Thanks spent the much around And your second from you. two, the your way or much this What $XX judge trial good Two any in on spend number assets this particularly and guidance million your our have around R&D like how and could XXXX but then a managed, could curious that OpEx quarter half. maybe in the two be for is this Hi, is being April delayed I'm set preclinical could It by managed? taking how appreciating reiterated the on Daiichi? how about year, guidance be be this to stone seems

Sheldon Koenig

part I'll first of second you. question. to morning, I'll and then part your question Ben of good it thank and for the the turn Hey, Dennis over take the

very prepared in that So the solved regarding we court our court happy are fact the our date, we said as emphasize remarks, first, the about again, me let way.

because this, a of of we when spoken anyhow. think trial that to we I milestone always is for know, been in you April the date Daiichi you targeted had Sankyo the As or later, was about timeline pushing had would due XXXX and XXXX have October

as going eye parties on that's both Xst said, to close of with that case, really the my the what's of very are material fact exchanging fact But answer, months. date. with the focused the about April, that XXXX updates And documents trial So an several I just March part court discovery, happening update focused there et over All forward now the the next of again, pushing cetera. you. to mentioned on awarded discovery, in is us the and parties Ben? be will we'll that be the initial really excited we're if certainly on are the right

Benjamin Halladay

thanks Dennis, the for Hey question.

to r we there pull still a things can regards we in as to and So expense, toggle levers have up or fair down d and of amount needed. room

still year, the we our, Outcomes validation half year, some it's from then second assets up is expense preclinical next wrap lingering that sort out for close For the the of trial related to rest the have the mostly that here. some or of two month production of the expense. But of in the should and

move with So up there's or of down things. those we a that fair both amount of can variability

Dennis Ding

it. Got Thank you.

Operator

question. moment our One next for

Serge from line the from Needham. comes question next of Our Belanger

line open. Your is

Serge Belanger

morning. Hi, good

Sheldon Koenig

Serge. Hi

Serge Belanger

guess higher partner. date a it follow around the April, and a expect given seen prescriptions they And and XXXX a or volumes expect I out ACC you you there? resolution be have do time? the on then can to with up meeting, impact nets potentially them legal could sales talk over of secondly, about overall to Thanks. you little Do longer proceedings from court improved, the your First that gross if since on this drag just the question, where we've

Sheldon Koenig

legal Again, Yes, to Ben take I'll question the over gross to I'll turn Serge. it as hi, relates it and to net.

What court been to, told really relates that's that tend you're of though resolved. April? question option give deference our the granted we is the is, any the interest courts what have I there even court decisions. it seeking appeal, respects in of And is an especially on approval in is trial to certain law event regulatory we've date by team the post-judgment is the appeal think we As before appellate owed, possible amount actually of to DSC approval the have would if --

the feel going that Again, have we always this will sooner case, though, cannot think the I we timing believe favor. versus a that my wanted. fact it have is We enough that important I again, And what's in had confidence and very later. heard is be trial express we that most ever that courts our strong to see we

So the before, on Ben, do as the can folks to the that's progress that I said now. we're making will that And again, comment relates as net? gross update it best want on we answer litigation. to I to always you

Benjamin Halladay

Serge. you, thank Yes,

this net So this to We've while we're help, for to in shape our pretty gross quarter while. net horizon focus in in but we're and little immediate a gross what's control the I Increased been and will for two point or within steady in one on state more term. necessarily will it's in at good controlling a we're the help, place will to a good we've for say a they volumes be that for year now. had And would laser and kind managing pretty, of that. not

following for the would while we'll incremental volumes label improvements, for been in state increase -- more we've I the see as expansion a post and but years, now. say So same

Serge Belanger

Thank you.

Operator

One moment question. for your next

of from from comes question Cowen. next Thome line Our Joseph

line Your open. is

Joseph Thome

physicians depth Hi there. at this these increase thank my the since have coming the Good seen, have Are taking in is maybe, you new, presentation for where increased and first prescribing Is seen getting from, therapy? how questions. you prescribers? morning prescription Maybe you ACC prescriptions? you one current the

about of can Daiichi footprint the hopefully you would that I maybe scale how granted, then on potentially relies the these you And expansions increase after much next your year, launch mentioned milestone? and much up leading you know label to how talk are full

talked you. or when question. but trial should longer? that in of, about April? that court quick think we you we about first it Obviously appeal, the from in Is of outcome? And we then last order if that date, expect about Thank sort read the that months three as of how happens should Kind on think the trial the April decision really initial

Sheldon Koenig

the to Eric, two first Joe. and the you do want legal I'll Thanks take question? take

Eric Warren

question, for Thanks Absolutely. Joe. the

seeing breadth both equal and and between across we're an seeing and prescribing, cardiology care Right So now at we're split increases, to we're primary cardiology. and about care. with regards depth so it primary

with current we've have we a we're relatively still changes pleased small and post really So the remember label. commercial footprint, And seen ACC. that on

over we footprint the to regards July With that XX the changes time, into sales mentioned as recently, effect about in Sheldon comments, Xth. added individuals opening to team went

to And got back the further anticipated year. the for that's plans additions So the this to we've label. half sales of prior force make to

as for the about. place put that into talked responsibility have did That's co-promotion team individuals products. we've also XX We that part that of Currax our PX

Sheldon Koenig

Great, is this to quickly. we Simple answer really matter of rapidly. question It how we make X.X contract your so made happen is, we've be of could pretty possibly filed, can the contract very on complaint believe it the a that actually that days, that regarding focusing and language take again, Joe, had it would decision thanks But public long second Eric. a would week. a that in a in of that's Section case occur decision?

Joseph Thome

Great, very thank you much.

Sheldon Koenig

Thank you.

Operator

One for next question question. next to Shrader will from of And moment come line our Thomas BTIG. our

Your open. line is

Thomas Shrader

taking question. for Good morning. Thanks the

You copay time. you in and for is reimbursed give that are can of that those sense patient what now? percentage average the and self-paid are prevention is? stable patients you. a of Is issues us support? patient support meaningful mentioned a have a primary you any We or Is copay yet scripts. Thank long where card And

Sheldon Koenig

want and B.J. that Eric, to start if you

Eric Warren

sure. Yes,

on and lot patient with at for of Tom that's so first exception that within said, that's pent-up tolerated statin label, on current question, been isn't to demand of With is a primary goal. prevention. primary ASCVD there patient our So our the not prevention their focus prevention, HeFH primary the maximally regards has the with

know, for the really you we contracts. primary change. prevention is our position CLEAR current have which B.J.? to upon right incorporated a going our label now, payer when put focus Outcomes label not primary As in patients, our been based data on has prevention strong and us But

Betty Swartz

approval Sure. are much an from key payers steps of Tom, X% some as positive said, prior with NEXLETOL to with our CLEAR approval improve. submission Sheldon that at mentioned been prepared as PA our continue have with rates extremely and over increase payers them. authorization and in up with remarks And results NEXLIZET as XX% and national rates

do but we buy a we have probably copay at each down copay, more down bringing that are for a commercial card average like $XX Our patients. for

a of services we NEXSTEP We helping services have done to also have our Navigator includes suite support with under pilot a reimbursement educate offices. that that

So step the and after an next is that upswing NEXLETOL showing all on clear NEXLIZET really all and statins.

Thomas Shrader

you. Thank Okay.

Operator

One our moment next question. for

question from line Bank from next Jason will of of Our America. Zemansky come the

line Your is open.

Jason Zemansky

trial disclosed specifics the you issues To what prior case haven't well, the date? any while to trial on here, forego the I itself? know would of disclose this, extent Good between on outside much you do our taking so keep comments the but here, but Appreciating thank limit what really to itself. can Daiichi’s morning. Thanks. two what to flexibility we Congratulations extent many sense resolving of there think of the And willingness you their the more a is parties of the questions. any harping the the to regarding amenable legal specifics the on a and couple quarter, be for to dispute. dialogue you on there's you

Sheldon Koenig

Great, Thank for question. your you hi Jason.

as having of the in suit. discussions to on our settlement any or legal ongoing with strategy comment now can't So we right DSC, discussions it type relates

in the mentioned that as XXXX and prepared then some expected again $XXX today, is and focusing owed approval, we're the Our earlier is of April timing following which the court the my secure in on. that of in put to full EMEA of us the first And contractually will the well. are that's half million what remarks we answers as date right goal we

cetera, relates the you and So we responsibility tell if fiduciary obviously approve now, or exist. we can take, take we best date as on you on like would I focusing that would as that, to that to that's And had focusing it we April. point. something the at Board like something doesn't court et or at my it's think this what what settlement we're time, that discovery to know, right And I that in mentioned, just

Jason Zemansky

contingency in EU or alternative along a of those plans something finding an as terms here Maybe any follow-up then, partner lines? potentially

Sheldon Koenig

nothing that we're Yes to that. it doing really, there's as relates

job continuous as we today, we're on and statin, partner and two that's showing outside for focusing have on As significant product. saying growth. years. Europe. the both the always are in something they and seeing next over been we this both And product marketing I been as think important Daiichi our we're the mentioned They've NEXLIZET well Sankyo, execution, is as that's since great a seeing heads also side, NEXLETOL they've mentioned, why we're doing we down growth that been and of that and U.S. is in this sides, both Esperion And were the U.S. after selling the

Jason Zemansky

Got it. the Thank color. for you

Operator

Thank Instructions] next our for you. One moment question. [Operator

comes Our H.C. of line Joseph Wainwright. from next from Pantginis question the

is open. line Your

Joseph Pantginis

everybody. Thanks for the Hi, morning. questions. taking Good

So you mind. don't two, if

pipeline for or before detailing maybe Ben, some Eric weeds I'm you prescribing getting any been details a what with commentary as to So my wait first management maybe to, the percentage prescriptions you've any habits? a changing on from going the provide then to Outcomes data, obviously process, is during data, and full lot. physicians into approval the impact prepared the say, the Thanks that data, you've you relative love comments, but regard said seen can the essentially for your CLEAR the just and with Sheldon, And on little more specifics with impacts? sharing for your cost regard more curious

Benjamin Halladay

Good thank for thanks and the morning Yes, question. you.

data our maximize that. technologies great as of to where meaningfully gotten we're here, done the putting we've We've assets spend. as progressing it while spending, far AI we pipeline and managing job put those money where big smart of So a leveraging very and goes sort sort for about

leverage or lot do something spend it's much as amount, if but I forward. Even on we say would we a those that work a it's move much that we've reasonable as little still And and we can in that year comments, potentially it of that doing. think next in we something that depending invest middle prepared of I mentioned on commercial is both I how want, we as as can the the but still, have runway toggle. can we extend and and cash we further want, spend had as the pipeline some of we're stuff think until much I we

Eric Warren

I'll Joe. take part. the then And second Thanks It’s Eric.

not with maximally the have our which sales have ASCVD ability teams process, activities because team, so data. from So but They team engaged well England hand the out have commercial to focus isn't marketing our that's Unfortunately, a not our at statin, as digital CLEAR do been current on our is to well Journal, patient not as in the New goal. label to discussions. updated, from able to detailing regards commercial the on via JAMA, and discuss Outcome reprint as the tolerated the continued as strategy,

So on that based But strategy. they've for been upon the increases appreciation these said, clinician seeing we're with data.

to our execute continue So on goal is to this.

as said, key that well tolerated statin on primary we and to that in I've mentioned limitations ASCVD treatment the the but past in just prevention. expand a that of population. some focus as high-risk desire shedding is With lot the maximally the there of patient that have, pulling

We'll seeing footprint. able we population. this us the we'll will about and with the CLEAR expand that we're expand commercial what talk to type now, happens, When of with data. pleased expand isn't very evidence Outcomes the but we're I'm So promoting

that's exponential phase So about. talked growth we the that

Joseph Pantginis

Great. I you. appreciate the comments. Thank

Eric Warren

welcome. You’re

Operator

from One the for And you. our question. come Securities. of question from line Jason Butler will next next moment our Thank JMP

is Your line open.

Jason Butler

question. the taking for thanks Hi,

Just treatment you and you're process on treatment to dynamics since changes time used any the getting changes for there the seeing Thanks. reimbursement if reimbursed rate then us before drug drug and could or physicians give color is Have in getting ACC? guess, or any any supports Is ordering. that decision approval being you more other And that I when seen just about patients? from the now color wondering is easier versus any ACC. one

Sheldon Koenig

to and you do first BJ, part the want second? the Eric answer to

Betty Swartz

Yes.

when based as time life. up that certainly, over noticed and the key much actually the really what authorization on So have rates well presentations spending is put be and we've with an laser the of just the a overall had, and rate. as really with as the on the that focus been our What educating payers as authorization this XX% prior national seen with on we an requirements Certainly, to approved you see payers XX% the increase has by of tactics certain demand, is prior with this. just and education, has helped approval we've offices on offices the educating some which pharmacy also

improvement over continue So year. we've actually but we anticipate and quarter again, the seen to will the great last we a closer versus we get, label and with improve, the last

Eric Warren

percentage regards of the would since ASCVD because again, have recipients on focus seen then, tolerated both I excitement I primary Still, been care. increased changes increases a And on in say, the as cardiology any statin been as cardiology as ACC, they well perspective, there's to the dynamic we've so with maximally is Jason, not data. mentioned, patient goal. a from

seen have in the increases as based We seen Still association but CLEAR Outcomes. as NEXLETOL. NEXLETOL, our is well the press again leader, in NEXLETOL you between upon will, increases and NEXLIZET we've if

for expand label again change. post will brands, and growth label our we exponential So anticipate both

Jason Butler

any that before those that you're that -- in use just Eric, color NEXLETOL, used scenarios increase follow-up a The being -- in does there? there. of ezetimibe in And evidence quick or any

Eric Warren

Yes.

Jason. to, starting So

But Outcomes surveys ezetimibe secondary and has done population CLEAR familiar surveys, their prevention based you know, we've Outcomes CLEAR X% many to So data, very with that upon seeing quantitative the go where tends benefit in ezetimibe, have we you're Outcomes yes, and as data. still a down early.

early down, the again, now So benefits. any of and still will we're promoting come not ezetimibe Outcomes CLEAR

Operator

Thank you. for Sheldon queue. remarks. the to in call like And the I'm not showing over to any closing back further I'd turn questions

Sheldon Koenig

much. Great, thank so you

and interest their just First want for and of of all, questions Esperion. to support your I everybody their thank

I the what obviously quarter a we've delivered Just you fact demonstrated all this growth expectations. would of key leave beat And again, couple that KPIs. We is we've with. points across

and happy scheduled a with the we win on approval our with significant being even growing see full then milestones, the We're next. Outcomes we again, prescriptions case where as very it behind of study. litigation our and And for It's track after statin, And supported that's seeing us. are April really in CLEAR XXXX. key we're having again, label We before, the us. by said XX,XXX-patient without currently lastly, we're

thank look talking to soon. forward So you you and a all to great day. again of Have

Operator

conference This concludes Thank you today's for call. participating.

disconnect. Everyone, have day. great now may a You

Esperion Therapeutics (ESPR) 1 Aug 232023 Q2 Earnings call transcript